Zentalis Pharmaceuticals (NASDAQ:ZNTL) Raised to "Strong-Buy" at HC Wainwright

Key Points

• HC Wainwright has upgraded Zentalis Pharmaceuticals (NASDAQ:ZNTL) to a "strong-buy" rating, indicating increased confidence in the company's stock.
• Several analysts have differing opinions on Zentalis, with a consensus average rating of "Moderate Buy" and a target price of $8.20.
• Zentalis Pharmaceuticals has a market cap of $103.61 million and reported an earnings per share of ($0.37), beating the consensus estimate.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) was upgraded by investment analysts at HC Wainwright to a "strong-buy" rating in a report released on Thursday,Zacks.com reports.

Several other brokerages have also weighed in on ZNTL. Wedbush reaffirmed a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL traded up $0.09 during mid-day trading on Thursday, reaching $1.50. 496,995 shares of the stock were exchanged, compared to its average volume of 1,237,260. The company has a market capitalization of $107.85 million, a P/E ratio of -0.66 and a beta of 1.71. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $5.44. The business's 50 day moving average is $1.38 and its 200-day moving average is $1.54.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.19. Equities analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Raymond James Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $68,000. Sei Investments Co. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $107,000. Prudential Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $39,000. JPMorgan Chase & Co. boosted its stake in shares of Zentalis Pharmaceuticals by 75.7% in the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock valued at $2,605,000 after purchasing an additional 370,511 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $323,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.